Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer-Reference-Cited by-同舟云学术

Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer

Published:2023-06-16 Issue:8 Volume:41 Page:2069-2076
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Pellegrino Antony,Gandaglia Giorgio,de Angelis Mario,Fallara Giuseppe,Mazzone Elio,Stabile Armando,Pellegrino Francesco,Robesti Daniele,Leni Riccardo,Scuderi Simone,Cucchiara Vito,Cirulli Giuseppe Ottone,Barletta Francesco,Montorsi Francesco,Briganti Alberto

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-023-04460-6.pdf

Reference27 articles.

1. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642

2. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8

3. Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R et al (2016) New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 70(1):161–175

4. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123(11):4918–4922

5. Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75(3):410–418

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging;Current Opinion in Urology;2024-04-05

2. Current Management and Future Treatment Strategies for Patients with Metastatic Hormone-Sensitive Prostate Cancer;World Journal of Urology;2023-07-31

3. Pushing the boundaries: Emerging role of radical prostatectomy as part of multimodal treatment for oligometastatic prostate cancer;Central European Journal of Urology;2023